Sanofi relies on AI: three times more success in medication development!

Sanofi relies on AI: three times more success in medication development!

Hessen, Deutschland - Sanofi Austria relies on the use of artificial intelligence (AI) to promote the development of medication. In an interview, Michael Kubischik, Managing Director of Sanofi Austria, reports that the company endeavors to increase the success rate of medication that reaches market maturity from the current 10% to 30%. This is to be realized by using AI in different phases of the development process. Especially in the early phase of medication development, where AI is used to use "virtual patients", a reduction in real number of participants could be achieved, while at the same time it is possible to predict effectiveness faster. According to [Leadersnet] (https://www.leadersnet.at/91771,mit-ki-wollen--the success probability-in-der.html), Sanofi plans to develop medication that are either the first or best of your therapy class.

Background of this initiative is the increasing importance of AI in the Biopharma industry. The [vfa] (https://www.vfa.de/de/forschung-kdukt/ Medizinische-biotechnology/kuenstliche-intelligenz- Fuer-drug development-and-supply) emphasizes that KI can not only increase the number of molecules that could be considered as a starting point for new active ingredients, but can also increase efficiency in the selection of potential active ingredients. This superior selection with the help of AI could lead to fewer dropouts in the clinical phase and ultimately enable more drugs.

challenges and markets

For Cubishics, cross -border cooperation between Germany, Austria and Switzerland is a decisive factor. Different regulatory systems in these countries represent a challenge. Sanofi sees itself as a "immunology Powerhouse" that wants to deepen the understanding of the human immune system in order to develop therapies for immunologically related diseases. The commitment of Sanofi goes beyond pure medication development; Social responsibility in relation to security of supply and prevention is also emphasized. In over 40 low -income countries, Sanofi is working to improve access to affordable medical devices.

The corporate strategy is supported by a strong focus on a healthy working environment. Sanofi promotes initiatives under the motto "Move Often, Eat Well, Stay Healthy" to secure the health of the employees. Sports opportunities, healthy meals and preventive programs are part of this health promotion.

digitization and AI potential

The general development of the world of work through digitization and the increased use of AI is also emphasized. Hessian.ai describes that Hessen as a location with a high digitization density in the key industries has great potential for the development and use of AI technologies. This region actively promotes this development and sees a driver of added value in the AI.

Sanofi pursues the goal of reaching net-zero greenhouse gas emissions by 2045 and acting more sustainably along the entire value chain. These ambitions show that the company not only attaches importance to technological innovation, but also on sustainability.